ArticleScientific reports2025
Anticancer potential of nanoemulsion-treated white mulberry and its leaves on MCF-7 cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
White mulberry leaf nanoemulsion (WML-NE) showed much higher antiproliferative activity against human breast cancer MCF-7 cells than a fruit-based nanoemulsion (WM-NE). After 48 h of exposure, WML-NE had only half the IC₅₀ value (14.52 µg/mL) compared to that of WM-NE (29.23 µg/mL), which means that WML-NE was almost twice as potent cytotoxic. The inclusion of nanoformulations in the experiment led to a significant decrease in the number of living cells, the appearance of apoptosis, and the halt of the cell cycle at phase G0/G1, thus, the anticancer agents might be involved in the execution of programmed cell death and growth inhibition pathways. Breast cancer is still one of the main causes of death from cancer all over the globe, this fact pointing out the requirement for new therapeutic approaches that are safe, effective, and of natural origin. Morus alba, a plant rich in flavonoids, phenolic acids, and other phytochemicals, is a good source of health-beneficial bioactive agents. Loading these substances into nanoemulsion delivery systems improves their solubility, stability, and uptake by cells, thereby intensifying their pharmacological activity. Overall, this research lays the groundwork for utilizing mulberry leaves as a novel plant-based nanotherapeutic agent with the highest efficiency. Accordingly, these findings can be used to propose the application of mulberry-derived nanoemulsions as auxiliary or alternative methods in breast cancer treatment and, thus, further in vitro and in vivo studies can contribute to their validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.